CLINICALLY SIGNIFICANT DRUG-INTERACTIONS WITH THE ORAL ANTICOAGULANTS

被引:44
作者
FREEDMAN, MD
OLATIDOYE, AG
机构
[1] Johns Hopkins University School of Medicine, Baltimore, Maryland
[2] Sinai Hospital of Baltimore, Baltimore, Maryland
[3] Department of Internal Medicine, Section of General Internal Medicine, Sinai Hospital of Baltimore, Baltimore, Maryland, 21215
关键词
D O I
10.2165/00002018-199410050-00003
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
Oral anticoagulants were introduced in the late 1940s and remain widely used today. Indications include prevention of thrombosis associated with atrial fibrillation, structural cardiac diseases and following prosthetic valvular replacement. They have been used for both treatment and prophylaxis of deep venous thrombosis and in efforts to decrease the frequency and rate of second myocardial infarction. These compounds include the coumarin derivatives [dicoumarol (bishydroxycoumarin), phenprocoumon, nicoumalone (acenocoumarol)] and the indanedione derivatives (diphenadione, phenindione. anisindione) which, because of adverse reactions, are largely unavailable. The oral anticoagulants, and warfarin in particular, are highly interactive with other drugs. Mechanisms of those interactions include both pharmacokinetic and pharmacodynamic mechanisms and may result in either hyper- or hypoprothrombinaemia. Because their principal adverse reaction is haemorrhage, and interactions are widespread across many therapeutic specialties, it becomes imperative for the practising physician to be aware of the possibility of interaction whenever these agents are coadministered with other drugs.
引用
收藏
页码:381 / 394
页数:14
相关论文
共 152 条
[61]  
Kerin N.Z., Blevins R.D., Goldman L., Faitel K., Rubenfire M., The incidence, magnitude, and time course of the amiodarone-warfarin interaction, Archives of Internal Medicine, 148, pp. 1779-1781, (1988)
[62]  
Koren J.F., Cochran D.L., Lanes R.L., Tolmentin-warfarin interaction, American Journal of Medicine, 82, pp. 1278-1279, (1987)
[63]  
Krstenansky P.M., Jones W.N., Garewal H.S., Effect of dicloxacillin sodium on the hypoprothrombinemic response to warfarin sodium, Clinical Pharmacology, 6, pp. 804-806, (1987)
[64]  
Lader E., Yang L., Clarke A., Wafarin dosage and vitamin K in Osmolite, Annals of Internal Medicine, 93, pp. 373-374, (1980)
[65]  
Leor J., Matetzki S., Oflaxacin and warfarin, Annals of Internal Medicine, 109, (1988)
[66]  
Leor J., Levartowsky D., Sharon C., Interaction between nalidixic acid and warfarin, Annals of Internal Medicine, 107, (1987)
[67]  
Link K.P., The anticoagulant from spoiled sweet clover, Harvey Lectures, 39, pp. 162-216, (1943)
[68]  
Link K.P., Discovery of dicumarol and its sequels, Circulation, 19, pp. 97-107, (1959)
[69]  
Linville T., Matanin D. Norfloxacin and warfarin, Annals of Internal Medicine, 110, pp. 751-752, (1989)
[70]  
Linville D., Emory C., Graves L., Ciprofloxacin and warfarin interaction, American Journal of Medicine, 90, (1991)